Adding Roche's immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread ...

Regulatory action was based on data from the Phase III IMforte trial, which showed that Zepzelca plus Tecentriq significantly ...

FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) Tuesday said that the U.S. Food and Drug Administration (FDA) has granted priority review for the supplemental New Drug Application (sNDA) for Zepzelca ...

Recent trials unveil significant advances in cancer treatment with immunotherapy drug Tecentriq, showing a 50% reduction in ...

Jazz Pharmaceuticals (JAZZ) stock gains as its lung cancer therapy Zepzelca, in combination with Roche's Tecentriq, receives ...

The FDA granted priority review to the combination of lurbinectedin and atezolizumab as a first-line maintenance therapy for ...

Brian P. Mulherin, MD, shares his key takeaways from the 2025 ASCO Annual Meeting, highlighting significant advancements in SCLC and the challenge of information overload at large conferences.

Inflammatix, a leader in AI-powered immune response diagnostics, today announced the appointment of Martín Vazquez as chief operating officer (COO). The hire marks a major milestone in the company's ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...